Finance ForgeBETA
Crear cuenta gratis
1)Empresas2)Rankings3)Iniciar sesión
Finance Forge Terminal v1.49.5
PrivacidadTérminosCookiesAviso Legal
● Connected
BMY US Equity
BRISTOL MYERS SQUIBB CO
59.12USD▼ 0.77%
Healthcare
Drug Manufacturers - General
96)Comparar97)Tesis →
Market Cap
$120.8B
Shares Outstanding
2.0B
— Annual —FY2025
Revenue
$48.2B
Gross Margin
71.1%
Net Margin
14.6%
FCF Margin
26.6%
ROE
38.2%
Current Ratio
1.26
D/E Ratio
2.43
Dividend Yield
4.2%
FCF / Share
6.29
Book Value / Share
9.04
BMY US Equity
59.12USD▼ 0.77%
Tesis →

BRISTOL MYERS SQUIBB CO (BMY): análisis fundamental y valoración

BRISTOL MYERS SQUIBB CO cotiza a 59.12 USD y tiene una capitalización bursátil de $120.8B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud

Price History
Loading...
Perfil
BolsaNYSEPaísUnited StatesEmpleados32,500Beta0.23Web↗ www.bms.com

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo …

Múltiplos de Valoración
P/E (Annual)
17.1×
P/E (TTM)
—
P/FCF (Annual)
9.4×
P/FCF (TTM)
—
EV/EBITDA
—
EV/Revenue
3.2×
P/Sales
2.5×
P/Book
6.5×
Rentabilidad (Último Anual)
Gross Margin
71.1%
Operating Margin
—
Net Margin
14.6%
FCF Margin
26.6%
ROE
38.2%
ROCE
—
ROA
7.8%
Effective Tax Rate
24.4%
Métricas TTM
Revenue TTM
—
Gross Profit TTM
—
Operating Income TTM
—
Net Income TTM
—
FCF TTM
—
EPS TTM
—
Quarters Used
—
TTM Period
—
Solidez del Balance
Net Debt
$34.6B
Net Debt / EBITDA
—
Debt / Equity
2.43
Current Ratio
1.26
Interest Coverage
—
Working Capital
$6.0B
Book Value / Share
9.04
Net Debt / Share
16.95
Crecimiento (YoY)
Revenue YoY
-0.2%
Net Income YoY
+178.8%
FCF YoY
-7.9%
EPS Diluted YoY
+178.5%
Retorno al Accionista
Dividend Yield
4.2%
Payout Ratio
71.5%
FCF / Share
6.29
CapEx % Revenue
2.7%
Rev / Employee
1M
Próximos Eventos
Ex-Dividendo
2026-10-02
Pago Dividendo
2026-11-02
Historial EPS
Periodo2026-102026-072026-042026-02
Real—$2.04$1.58$1.26
Estimado$1.70$1.60$1.42$1.20
Sorpresa—+27.5%+11.3%+5.0%
Empresas similares
Smart Money
vs Sector: Healthcare (1130 empresas)
MétricaBMYMediana SectorΔ
Gross Margin71.1%57.0%+14.0%
Operating Margin—-38.6%—
Net Margin14.6%-33.6%+48.2%
FCF Margin26.6%-13.9%+40.5%
ROE38.2%-40.4%+78.6%
ROA7.8%-32.0%+39.8%
Current Ratio1.262.84-1.58
Debt / Equity2.430.28+2.15
Scoring Fundamental
Capital Allocation
4/ 8Moderada
✓FCF+Free cash flow positivo
✓FCFmMargen FCF > 10%
✓DilucSin dilución significativa (< 2%/año en 3 años)
✗Rev↑Revenue CAGR 3 años > 5%
✗ROCERetorno sobre capital empleado > 10%
✗DeudaDeuda neta/EBITDA < 3× (o posición de caja neta)
✗Mg↑Margen operativo ≥ hace 2-3 años (tolerancia -2pp)
✓Inv.R&D + Capex > 3% de revenue (reinversión en el negocio)